ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

5 Advances in Alzheimer’s Care and Treatment in 2025

photo

SPONSORED CONTENT -- (StatePoint) For the millions of Americans touched by Alzheimer’s disease, 2025 brought major advances in understanding of brain health and progress in diagnosis and treatment. Here are the year’s biggest advances, along with how you can take action with this knowledge in 2026:

1) A structured plan can sharpen brain health.

In a major U.S. clinical trial of older adults at risk for cognitive decline, two healthy lifestyle plans in the Alzheimer’s Association’s U.S. POINTER study improved memory and thinking skills over two years. Both interventions included exercise, brain-healthy nutrition, cognitive training and heart health monitoring. However, participants in a highly structured program that also included regular coaching and peer support showed significantly greater brain health gains, demonstrating that when brain-healthy habits are organized and supported, people stick with them and thinking skills benefit.

Next steps for families: Start small but structured: aim for 150 minutes of weekly exercise of at least moderate intensity, Mediterranean-style meals, 7–8 hours of sleep per night, and 2–3 short brain-training sessions each week. Put goals on a shared calendar, find an exercise or brain-health buddy, and schedule regular check-ins with your clinician or healthcare professional.

2) Simple blood tests can help spot changes earlier.

In 2025, the U.S. Food and Drug Administration (FDA) cleared two blood tests that detect Alzheimer’s-related brain changes, offering a less invasive, less expensive option for those experiencing memory changes to support diagnosis and potentially reduce the need for PET scans or spinal taps. Blood tests are not stand-alone diagnostic tools, but their use can help guide next steps for testing, treatment and planning. The Alzheimer’s Association has developed clinical guidelines to help specialists determine when to use blood tests alongside established “gold standard” tests and clinical judgment.

Next step for families: Ask your health care team whether an Alzheimer’s blood test makes sense for you or a loved one, and how your results would affect lifestyle and health care plans. If they recommend testing, ask them to refer you to a specialist who can explain the results and next steps.

3) Americans want to know and act sooner.

A recent Alzheimer’s Association national survey of adults 45 and older found most want to learn early if they have Alzheimer’s before symptoms impact their lives, and 9 out of 10 would take a simple test, if available, to clarify next steps. Nearly 3 in 5 respondents said they would accept a moderate or high level of risk to take medication that could slow the disease’s progression.

Early awareness unlocks time to live healthfully, organize support, consider treatment options, and plan finances and care preferences.

Next step for families: Bring your top concerns, what’s changed (memory, mood, function), and goals for the next three months to your next appointment.

4) Treatment can be easier to take.

The August 2025 FDA approval of Leqembi for delivery via weekly subcutaneous injections may ease treatment for some patients. Those who complete initial infusion treatments as directed for 18 months can now receive their subsequent weekly treatment using at-home autoinjectors.

Fewer infusion clinic visits can mean less travel and lower caregiver burden, making it easier to stick to treatments for eligible patients. Decisions depend on eligibility, monitoring requirements, side-effect profile, and your clinician’s judgment.

The Alzheimer’s Association encourages clinician participation in ALZ-NET, a nationwide program collecting real-world data on Alzheimer’s treatments.

Next step for families: If treatment is on the table, ask whether at-home injections might be an option after the initial phase, and what monitoring you’d still need.

5) A new clinician hub helps care teams stay current.

When clinicians have fast access to evidence-based resources, patients get clearer answers and more consistent care. The new centralized professional portal, ALZPro, launched by the Alzheimer’s Association, now curates practice guidelines, professional training, and point-of-care tools for earlier detection, appropriate test use, treatment eligibility and safety monitoring.

Next step for families: Let your health care professional know that the Alzheimer’s Association has new research, training and support materials for professionals.

For information, support, research and public policy, visit The Alzheimer’s Association at alz.org or call 800.272.3900.

From new diagnostic tools and treatments to proven lifestyle plans, major advances in Alzheimer’s in 2025 can change how you manage the disease in 2026.

*****

Photo Credit: (c) DisobeyArt / iStock via Getty Images Plus

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.28
+0.00 (0.00%)
AAPL  278.03
+0.00 (0.00%)
AMD  221.43
+0.00 (0.00%)
BAC  54.56
+0.00 (0.00%)
GOOG  313.70
+0.00 (0.00%)
META  652.71
+0.00 (0.00%)
MSFT  483.47
+0.00 (0.00%)
NVDA  180.93
+0.00 (0.00%)
ORCL  198.85
+0.00 (0.00%)
TSLA  446.89
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.